RT Journal Article
SR Electronic
T1 The reversion variant (p.Arg90Leu) at the evolutionarily adaptive p.Arg90 site in CELA3B predisposes to chronic pancreatitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.28.20240135
DO 10.1101/2020.11.28.20240135
A1 Masson, Emmanuelle
A1 Rebours, Vinciane
A1 Buscail, Louis
A1 Frete, Frédérique
A1 Pagenault, Mael
A1 Lachaux, Alain
A1 Chevaux, Jean-Baptiste
A1 Génin, Emmanuelle
A1 Cooper, David N.
A1 Férec, Claude
A1 Chen, Jian-Min
YR 2020
UL http://medrxiv.org/content/early/2020/11/30/2020.11.28.20240135.abstract
AB A gain-of-function missense variant in the CELA3B gene, p.Arg90Cys (c.268C>T), has recently been reported to cause pancreatitis in an extended pedigree. Herein, we sequenced the CELA3B gene in 644 genetically unexplained French chronic pancreatitis (CP) patients (all unrelated) and 566 controls. No predicted loss-of-function variants were identified. None of the six low frequency or common missense variants detected showed significant association with CP. Nor did the aggregate rare/very rare missense variants (n=14) show any significant association with CP. However, p.Arg90Leu (c.269G>T), which was found in 4 patients but no controls and affects the same amino acid as p.Arg90Cys, serves to revert p.Arg90 to the human elastase ancestral allele. Since p.Arg90Leu has previously been shown to exert a similar functional effect to p.Arg90Cys, our findings not only confirm the involvement of CELA3B in the etiology of CP but also pinpoint a new evolutionarily adaptive site in the human genome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThis work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM), France. The funding source did not play any roles in the study design, collection, analysis, and interpretation of the data and in the writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Brest University ethical review committee approved this study. All patients gave informed consent for genetic analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as supplementary information.